Drug Profile
Research programme: anti-cancer therapeutics - CASI Pharmaceuticals
Alternative Names: CASI 001; CASI 002Latest Information Update: 07 Sep 2023
Price :
$50
*
At a glance
- Originator CASI Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer